検索
Spero Therapeutics Inc
SPROウォッチリストに追加
1.195USD
+0.015+1.27%
終値 07-28 16:00（ET）15分遅れの株価
69.18M時価総額
4.30直近12ヶ月PER
詳細情報 Spero Therapeutics Inc 企業名
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on identifying and developing novel treatments for rare diseases and diseases caused by multi-drug resistant (MDR) bacterial infections with unmet need. Its product candidate SPR720 is an investigational, chemically stable phosphate ester prodrug that is converted in vivo to SPR719 for the treatment of nontuberculous mycobacterial (NTM) pulmonary disease. Its clinical stage product candidate, tebipenem HBr is an investigational oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections (cUTIs) including acute pyelonephritis (AP) to help patients potentially reduce duration of in-patient therapy.
Spero Therapeutics Incの企業情報
企業コードSPRO
会社名Spero Therapeutics Inc
上場日Nov 02, 2017
最高経営責任者「CEO」Rajavelu (Esther)
従業員数32
証券種類Ordinary Share
決算期末Nov 02
本社所在地675 Massachusetts Ave Ste 14
都市CAMBRIDGE
証券取引所NASDAQ OMX - NASDAQ BASIC
国United States of America
郵便番号02139-3309
電話番号18572421600
ウェブサイトhttps://sperotherapeutics.com/
企業コードSPRO
上場日Nov 02, 2017
最高経営責任者「CEO」Rajavelu (Esther)
Spero Therapeutics Incの経営陣
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
81.45K
+12.28%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
65.00K
+15.38%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
65.00K
+15.38%
Ms. Kathleen Tregoning
Ms. Kathleen Tregoning
Independent Director
Independent Director
65.00K
+15.38%
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Dr. Patrick Volkert Jozef Johannes Vink, M.D.
Lead Independent Director
Lead Independent Director
--
--
Dr. John C. Pottage, Jr., M.D.
Dr. John C. Pottage, Jr., M.D.
Independent Director
Independent Director
--
--
Mr. Scott T. Jackson
Mr. Scott T. Jackson
Independent Director
Independent Director
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Dr. Ankit Mahadevia, M.D.
Dr. Ankit Mahadevia, M.D.
Non-Executive Director
Non-Executive Director
364.22K
-1.80%
Mr. Timothy (Tim) Keutzer
Mr. Timothy (Tim) Keutzer
Chief Operating Officer
Chief Operating Officer
335.13K
+55.82%
Ms. Esther Rajavelu
Ms. Esther Rajavelu
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
President, Chief Executive Officer, Chief Financial Officer, Treasurer and Chief Business Officer
229.84K
-10.98%
Dr. Milind S. Deshpande, Ph.D.
Dr. Milind S. Deshpande, Ph.D.
Independent Director
Independent Director
81.45K
+12.28%
Mr. Frank E. Thomas, CPA
Mr. Frank E. Thomas, CPA
Independent Chairman of the Board
Independent Chairman of the Board
65.00K
+15.38%
Ms. Cynthia Smith
Ms. Cynthia Smith
Independent Director
Independent Director
65.00K
+15.38%
よくある質問
Spero Therapeutics Incの上位5名の株主は誰ですか？
Spero Therapeutics Incの上位5名の株主は以下のとおりです。Dr. Ankit Mahadevia, M.D.
Spero Therapeutics Inc（SPRO）の株式を保有している機関の数はいくつですか？
2026Q1時点で、Spero Therapeutics Incの株式を保有している機関は117社あり、保有株式の総市場価値は約11.81Mで、全体の20.40%を占めています。2025Q4と比較して、機関の持ち株は-1291189.00増加しています。
Spero Therapeutics Incの最大の収益源は何ですか？
2026Q1において、Collaboration Revenue Related Party部門がSpero Therapeutics Incにとって最大の収益を生み出しており、その金額は47.03Mで、全収益の70.41%を占めています。